Real-World tagrisso study shows promise for lung cancer patients

NCT ID NCT03918304

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how well the drug Tagrisso (osimertinib) works and how safe it is for people with a certain type of lung cancer (non-small cell lung cancer with EGFR mutations) in everyday medical practice. Over 900 patients in Korea were observed while taking Tagrisso as their only treatment. The goal was to track side effects and see how long the drug kept the cancer from growing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tagrisso (osimertinib)
What this could lead to: If successful, this study could confirm that Tagrisso works well and is safe for a broad range of patients with EGFR-mutant lung cancer in everyday clinical practice.
What could go wrong: This is an observational study, not a controlled trial, so results may be less definitive. Side effects like skin rash or diarrhea are possible, and the drug may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, NON-SMALL-CELL LUNG

Contacts and locations

Locations

Research Site

Busan, South Korea
Research Site

Chungcheongbuk-do, South Korea
Research Site

Daegu, South Korea
Research Site

Daejeon, South Korea
Research Site

Gangwon State, South Korea
Research Site

Gyeonggi-do, South Korea
Research Site

Incheon, South Korea
Research Site

Jeollabuk-do, South Korea
Research Site

Jeollanam-do, South Korea
Research Site

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.